Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials

Sara Bringhen, Maria Victoria Mateos, Sonja Zweegman, Alessandra Larocca, Antonietta Pia Falcone, Albert Oriol, Davide Rossi, Maide Cavalli, Pierre Wijermans, Roberto Ria, Massimo Offidani, Juan Jose Lahuerta, Anna Marina Liberati, Roberto Mina, Vincenzo Callea, Martijn Schaafsma, Chiara Cerrato, Roberto Marasca, Luca Franceschini, Andrea EvangelistaAna Isabel Teruel, Bronno van der Holt, Vittorio Montefusco, Giovannino Ciccone, Mario Boccadoro, Jesus San Miguel, Pieter Sonneveld, Antonio Palumbo

Research output: Contribution to journalArticlepeer-review

Abstract

Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these patients, treatmentrelated side effects are frequent and full drug doses difficult to tolerate. We retrospectively analyzed data from 1435 elderly patients enrolled in 4 European phase III trials including thalidomide and/or bortezomib. After a median follow up of 33 months (95%CI: 10-56 months), 513 of 1435 patients (36%) died; median overall survival was 50 months (95%CI: 46-60 months). The risk of death was increased in patients aged 75 years or over (HR 1.44, 95%CI: 1.20-1.72; P

Original languageEnglish
Pages (from-to)980-987
Number of pages8
JournalHaematologica
Volume98
Issue number6
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials'. Together they form a unique fingerprint.

Cite this